18
Participants
Start Date
June 1, 2021
Primary Completion Date
March 31, 2023
Study Completion Date
September 30, 2023
Hypofractionated radiotherapy
"Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
Concurrent chemotherapy
weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
Consolidation immunotherapy
Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
Sun yat-sen University Cancer Center, Guangzhou
Sun Yat-sen University
OTHER